Raltegravir
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| + | <applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="___, better known as ___, ([[___]])"/> | ||
| + | ===Better Known as:=== | ||
| + | * Marketed By: <br /> | ||
| + | * Major Indication: [[Human Immunodeficiency Virus]] Infection<br /> | ||
| + | * Drug Class: | ||
| + | * Date of FDA Approval (Patent Expiration): <br /> | ||
| + | * 2009 Sales: | ||
| + | * Importance: | ||
| + | * The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | ||
| + | |||
| + | ===Mechanism of Action=== | ||
| + | |||
===Pharmacokinetics=== | ===Pharmacokinetics=== | ||
{| class="wikitable" border="1" width="40%" style="text-align:center" | {| class="wikitable" border="1" width="40%" style="text-align:center" | ||
| Line 40: | Line 52: | ||
! Hepatic - (CYP3A4) | ! Hepatic - (CYP3A4) | ||
|} | |} | ||
| + | |||
| + | ===References=== | ||
| + | <references/> | ||
| + | __NOEDITSECTION__ | ||
| + | __NOTOC__ | ||
Revision as of 16:54, 7 December 2010
|
Better Known as:
- Marketed By:
- Major Indication: Human Immunodeficiency Virus Infection
- Drug Class:
- Date of FDA Approval (Patent Expiration):
- 2009 Sales:
- Importance:
- The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information
Mechanism of Action
Pharmacokinetics
| Retroviral Integrase Inhibitor Pharmacokinetics [1][2] | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | Raltegravir | Elvitegravir | |||||||||
| Tmax (hr) | 1.8 | 2-4 | |||||||||
| Cmax (ng/ml) | 4253 | 2070 | |||||||||
| Bioavailability (%) | 32 | ~30 | |||||||||
| Protein Binding (%) | 83 | N/A | |||||||||
| T1/2 (hr) | 10.8 | 7.6 | |||||||||
| AUC (ng/ml/hr) | 10168 | 21200 | |||||||||
| Dosage (mg) | 400 | 150 | |||||||||
| Metabolism | Hepatic - (UGT1A1) | Hepatic - (CYP3A4) | |||||||||
References
- ↑ A Gaur, et al. Pharmacokinetics and Safety of Once-Daily Elvitegravir in HIV-Infected Adolescents. 17th Conference on Retroviruses. Poster Number: 874.
- ↑ Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT, Breidinger SA, Mangin EC, Azrolan N, Greenberg HE, Haazen W, Stone JA, Gottesdiener KM, Wagner JA. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2008 Dec;52(12):4338-43. Epub 2008 Oct 6. PMID:18838589 doi:10.1128/AAC.01543-07
